Cart
sales@molnova.com
SRI-29329
CAS No. 2086809-58-5
SRI-29329( SRI29329 | SRI 29329 )
Catalog No. M13252 CAS No. 2086809-58-5
A potent, specific CDC-like kinase (CLK) inhibitor with IC50 of 78, 16 and 86 nM for CLK1, 2 and4, respectively; shows no significant activity for CLK3, CDK1, CDK4 and CDK6 (IC50>1,000 nM).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 215 | In Stock |
|
| 5MG | 188 | In Stock |
|
| 10MG | 307 | In Stock |
|
| 25MG | 520 | In Stock |
|
| 50MG | 733 | In Stock |
|
| 100MG | 1004 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameSRI-29329
-
NoteResearch use only, not for human use.
-
Brief DescriptionA potent, specific CDC-like kinase (CLK) inhibitor with IC50 of 78, 16 and 86 nM for CLK1, 2 and4, respectively; shows no significant activity for CLK3, CDK1, CDK4 and CDK6 (IC50>1,000 nM).
-
DescriptionA potent, specific CDC-like kinase (CLK) inhibitor with IC50 of 78, 16 and 86 nM for CLK1, 2 and4, respectively; shows no significant activity for CLK3, CDK1, CDK4 and CDK6 (IC50>1,000 nM).
-
In VitroSRI-29329 (compound 8) shows some modest (~5 fold) selectivity for CLK2 over CLK1 and CLK4 without significant CDK1,4,6 activity.
-
In Vivo——
-
SynonymsSRI29329 | SRI 29329
-
PathwayCell Cycle/DNA Damage
-
TargetCLK
-
RecptorCLK
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2086809-58-5
-
Formula Weight399.927
-
Molecular FormulaC20H26ClN7
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 50 mg/mL (125.03 mM)
-
SMILESCC(N1C=NC2=C(NC3=CC=CC(Cl)=C3)N=C(N[C@@H]4[C@@H](N)CCCC4)N=C12)C
-
Chemical NameN2-((1S,2S)-2-aminocyclohexyl)-N6-(3-chlorophenyl)-9-isopropyl-9H-purine-2,6-diamine
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Shi Y, et al. Bioorg Med Chem Lett. 2017 Feb 1;27(3):406-412.
molnova catalog
related products
-
T-025
T-025 (T025, CLK inhibitor T-025) is an orally available, potent inhibitor of Cdc2-like kinases (CLKs) with Kd of 4.8, 0.096, 6.5, and 0.61 nM for CLK1, CLK2, CLK3, and CLK4, also inhibits DYRK1A and DYRK1B with IC50 of 0.074 and 1.5 nM.
-
K00546
K00546 is a potent inhibitor of the CDC2-like kinase CLK1 and CLK3 with IC50 of 8.9 and 29.2 nM, respectively.
-
TG693
TG693 is an orally available, selective, ATP-competitive CLK1 inhibitor with IC50 of 112.6 nM.
